A Phase I, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs ETX 2514 (Primary) ; Sulbactam/ETX 2514 (Primary) ; Imipenem/cilastatin; Sulbactam
- Indications Acinetobacter infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Entasis Therapeutics
- 09 Oct 2017 According to an Entasis Therapeutics media release, data were presented at IDWeek 2017.
- 08 Oct 2017 Results presented at the IDWeek 2017
- 28 Sep 2017 According to an Entasis Therapeutics media release, data will be presented at IDWeek 2017.